Economics of hemophilia care

Haemostasis

Volumn 30, Issue 6, 2000, Pages 333-336

  Aledort, Louis M ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Comprehensive care; Economics; Factor replacement; Hemophilia; Immune tolerance

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; PROTHROMBIN COMPLEX;

ARTICLE; COST; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; HEALTH CARE DELIVERY; HEMOPHILIA A; HEMOPHILIA B; HUMAN; IMMUNOLOGICAL TOLERANCE; PATIENT CARE; PRIORITY JOURNAL;

EID: 0034444579     PISSN: 03010147     EISSN: None     Source Type: Journal    
DOI: 10.1159/000054151     Document Type: Article

References (13)

1. Aledort LM: Lessons from hemophilia (editorial). N Engl J Med 1982;306:607-608.
2. Lusher JM, Shapiro SS, Palascak JE, Rao AV, Levine PH, Blatt PM and the Hemophilia Study Group: Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII. N Engl J Med 1980;303:421-425.
3. Aledort LM, Cohen M, Hilgartner MW, Lipton R: Treatment of hemophiliacs with inhibitors: Cost and effect on blood resources; in Hoyer L (ed): Factor VIII Inhibitors. New York, Liss, 1984, pp 353-365.
4. Lipton RA: The economics of factor VIII inhibitor treatment. Semin Hematol 1994;31(suppl 4):37-38.
5. Mariani G, Ghirardini A, Belloco R: Immune tolerance in hemophilia -Principal Results from the International Registry: Report of the Factor VIII and IX Subcommittee. Thromb Hemost 1994;72:1:155-158.
6. Nilsson IM, Berntorp E, Zettervall O: Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. N Engl J Med 1988;318:947-950.
7. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H: Twenty-five years experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992;232:25.
8. Aledort EM, Haschemeyer RH, Pettersson H: A longitudinal study of orthopedic outcomes for severe factor VIII deficient hemophiliacs. J Intern Med 1994;236:391-399.
9. Bohn RE, Avorn J, Glynn RJ, Choodnovskiy I, Haschemeyer R, Aledort LM: Prophylactic use of factor VIII: Are the clinical benefits worth the additional cost? Blood Abstracts 1995;86:10:611a.
10. Schramm W: Personal communication.
11. Björkman S: Pharmacokinetics of factor VIII and factor IX: in Prophylactic Treatment of Hemophilia A and B: Current and Future Perspectives. York, Science & Medicine, 1994, pp 45-48.
12. Ross-Degnan D, Soumerai SB, Avorn J, Bohn RL, Bright R, Aledort LM: Hemophilia home treatment: Economic analysis and implications for health policy. Int J Technol Assess Health Care 1995;11: 327-344.
13. Liesner RJ, Vora AJ, Hann IM, Lilleymann JS: Use of central venous catheters in children with severe congenital coagulopathy. Br J Haematol 1995;91:203-207.